Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
Status:
Unknown status
Trial end date:
2020-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR
monoclonal antibody（SCT200）in patients with advanced esophageal squamous cell carcinoma
progressed following treatment with taxane/platinum/fluorouracil.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sinocelltech Ltd.
Collaborator:
Tianjin Medical University Cancer Institute and Hospital